Explore the latest news from Khondrion and its team.
Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today that its CEO Prof. dr. Jan Smeitink will present first results of Khondrion’s KHENERGY study at the Dutch Life Sciences Conference in Oss, The Netherlands, on November 22 at 10 am.
New Patents granted for Khondrion’s mitochondrial disease lead compound KH176 NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical...
Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical...
THE KHENERGYC STUDY: European Union EFRO grant to boost the development of Khondrion’s KH176 for children with mitochondrial...
Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes...
Press Release New EU research project REMIX joins forces between universities’ research facilities and Khondrion New EU...
2020 – A Year in Review As a new year approaches, Khondrion’s CEO Jan Smeitink reflects on 2020 and the progress Khondrion has made in its research...
1. Tell us about your role as Chief Early Development Officer at Khondrion. There are a lot of different aspects to my role. I help to steer the...
Estimated to affect more than 400 million people around the world, diabetes is one of the most common chronic disorders, with a range of different...
Mitochondrial diseases are a clinically, biochemically and genetically heterogeneous group of disorders. Signs, symptoms and the organs involved can...
Simple functions such as blinking and breathing are actions that we take for granted. However, for those living with Leigh...
1. Tell us about your career before joining Khondrion.I qualified as a Medical Doctor from the University of Utrecht and worked clinically in the...
